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Abstract  25 
Gram-negative bacteria possess a unique and complex cell envelope, composed of an inner 26 
and outer membrane separated by an intermediate cell wall-containing periplasm. This 27 
tripartite structure acts intrinsically as a significant biological barrier, often limiting the 28 
permeation of anti-infectives, and so preventing such drugs from reaching their target. 29 
Furthermore, identification of the specific permeation-limiting envelope component proves 30 
difficult in the case of many anti-infectives, due to the challenges associated with isolation of 31 
individual cell envelope structures in bacterial culture. The development of an in vitro 32 
permeation model of the Gram-negative inner membrane, prepared by repeated coating of 33 
physiologically-relevant phospholipids on Transwell® filter inserts, is therefore reported, as a 34 
first step in the development of an overall cell envelope model. Characterization and 35 
permeability investigations of model compounds as well as anti-infectives confirmed the 36 
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suitability of the model for quantitative and kinetically-resolved permeability assessment, and 37 
additionally confirmed the importance of employing bacteria-specific base materials for more 38 
accurate mimicking of the inner membrane lipid composition - both advantages compared to 39 
the majority of existing in vitro approaches. Additional incorporation of further elements of 40 
the Gram-negative bacterial cell envelope could ultimately facilitate model application as a 41 
screening tool in anti-infective drug discovery or formulation development. 42 
 43 
Keywords: Gram-negative bacterial cell envelope, permeation kinetics, permeability 44 
investigations, in vitro permeation model  45 
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CL  cardiolipin 47 
ER  electrical resistance 48 
IM  inner membrane 49 
KRB  Krebs-Ringer buffer 50 
LC  liquid condensed 51 
LE  liquid expanded 52 
MIC  minimal inhibitory concentration 53 
OM  outer membrane 54 
PC  phosphatidylcholine 55 
PL  phospholipid 56 
Papp  apparent permeability coefficient 57 
PBS  phosphate buffered saline 58 
PMB  polymyxin B 59 
POPE  1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine 60 
POPG  1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-rac-glycerol) 61 
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PVPA   phospholipid vesicle-based permeation assay 62 
SE  standard error of the mean 63 
SEM  scanning electron microscopy 64 
UHPLC ultra-high performance liquid chromatography 65 
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1. Introduction 86 
The increasingly reported occurrence of multidrug-resistant bacteria, particularly those of the 87 
Gram-negative classification, constitutes a growing threat to the state of health worldwide 88 
[1,2]. The up-regulation and evolution of bacterial resistance mechanisms, leading to 89 
inadequate drug levels at target sites, in fact acts to exacerbate the already challenging task of 90 
successfully delivering anti-infective compounds or formulations into or across the cell 91 
envelope [3]. The unique and complex structure of the Gram-negative bacterial envelope 92 
operates intrinsically as a significant barrier, preventing the attainment of sufficient drug 93 
levels at required sites of action in many instances [4,5]. The envelope itself consists of an 94 
inner membrane (IM) of phosphatidylethanolamine, phosphatidylglycerol and cardiolipin as 95 
principal phospholipid (PL) components, together with an asymmetric outer membrane (OM) 96 
composed of a PL-containing inner leaflet and a lipopolysaccharide-containing outer leaflet. 97 
These two membrane structures, additionally incorporating aspects of active transport, are 98 
chiefly responsible for the intrinsic barrier properties of the envelope, which is therefore 99 
commonly termed as a two-membrane barrier [6]. In addition however, the periplasmic space 100 
separating the IM and OM serves as an area of high metabolic activity [7], and also houses the 101 
peptidoglycan cell wall (a much thinner structure in comparison to Gram-positive bacteria). 102 
The described intrinsic and resistance-compounded difficulties in achieving adequate drug 103 
levels at bacterial target sites, together with the present low flow within the antibiotic 104 
development pipeline, both contribute to a common inability to successfully treat Gram-105 
negative bacterial infections. Such difficulties can ultimately and collectively be regarded as 106 
symptoms of a bacterial bioavailability problem [8], which is of vital importance to address. 107 
The development of new anti-infective compound classes, the discovery of new targets, and 108 
the advent of novel delivery strategies which facilitate effective anti-infective drug 109 
penetration into or completely across the cell envelope (in order to reach intracellular sites of 110 
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action) therefore all constitute important areas of research in this respect. In addition, research 111 
efforts within these areas require an increased understanding of and ability to investigate 112 
bacterial permeation processes - a difficult task to achieve currently in cellulo due to 113 
numerous associated challenges [8]. As such, a further research need to be addressed is the 114 
requirement for models which allow for the characterization and quantification of anti-115 
infective permeation across the Gram-negative bacterial cell envelope. Such models would 116 
provide complementary information to that obtained from established, ‘in cellulo’ efficacy 117 
testing approaches (such as determination of minimum inhibitory concentrations (MIC)), 118 
allowing for optimization of drug candidates with respect to their target interaction as well as 119 
their ability to sufficiently permeate the envelope barrier [9].  120 
 121 
A variety of in vitro models in fact already exist for investigating interactions between anti-122 
infective compounds and bacterial cell envelope components; these can generally be classified 123 
as electrophysiology models [10,11], Langmuir films [12] and vesicle-based assays [13]. 124 
While all such models are able to provide insight into bacterial permeation processes, they 125 
also demonstrate several shortcomings. For instance, most focus on approximating the IM or 126 
the OM alone, rather than both structures together (although some progress in this respect has 127 
been recently made [14]). Furthermore, the PL composition of existing IM models often 128 
deviates from that found in Gram-negative bacteria, in terms of either character or ratio [15]. 129 
The majority of the available approaches also do not allow for the quantification of 130 
permeation processes [14, 16-18], an important ability which would allow for more in-depth 131 
and accurate characterization of the way in which anti-infective compounds and formulations 132 
interact with the bacterial envelope barrier [19]. Hence, there is a great need for new models 133 
which represent the entire Gram-negative bacterial envelope with respect to both composition 134 
and structure, and which are specifically designed to yield high content, quantitative 135 
permeation information in a kinetically- and ultimately spatially-resolved manner. 136 
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 137 
As a first step in the production of an overall envelope model, this work is aimed at designing 138 
and characterizing an in vitro model of the Gram-negative bacterial IM employing bacteria-139 
specific PLs, which is explicitly designed to quantify the passive permeation kinetics of anti-140 
infectives. A Transwell®-based setup, mimicking the conventional procedure to assess 141 
permeation through mammalian cell barriers, was employed for the model preparation 142 
process. An existing approach for production of lipid-based mammalian membrane models – 143 
the phospholipid-vesicle based permeation assay (PVPA) [20] - was adapted in order to 144 
prepare the bacterial IM model, utilizing a bacteria-specific lipid composition as found in the 145 
IM of Gram-negative bacteria such as Escherichia coli and Pseudomonas aeruginosa [21]. 146 
The resulting preparation procedure was also employed to produce a model consisting solely 147 
of phosphatidylcholine, as a major phospholipid in mammalian cell membranes [20]. The IM 148 
model and the phosphatidylcholine-containing mammalian model (‘mammalian comparator’) 149 
were then directly compared at each stage of IM characterization and in subsequent 150 
permeability studies. This comparison was made in order to discern any lipid-dependent 151 
differences between the models in terms of structure and function, and in doing so, to clearly 152 
demonstrate the need to adapt an already existing mammalian lipid-based model using 153 
bacteria-relevant materials. Models were characterized with respect to the interfacial behavior 154 
of their component lipids, as well as integrity and robustness, topography, and thickness. 155 
Furthermore, sets of model compounds including anti-infectives were utilized to ultimately 156 
assess the impact of model lipid composition on permeability behavior, and to highlight the 157 
ability to obtain quantitative and kinetically-resolved permeation data. 158 
 159 
2. Material and methods  160 
 161 
2.1. Materials 162 
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1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (POPE), 1-163 
hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) 164 
(POPG) and 1,1',2,2'-tetra-(9Z-octadecenoyl) cardiolipin (sodium salt) (CL) purchased from 165 
Avanti Polar Lipids Inc. (Alabaster, AL, USA) were used for the IM model preparation. Egg 166 
phosphatidylcholine (PC, Lipoid E80) was kindly donated by Lipoid GmbH (Ludwigshafen, 167 
Germany), and employed for the mammalian comparator model. Polycarbonate filters with a 168 
pore size of 800 nm (Merck Millipore, Darmstadt, Germany) were used for liposome 169 
extrusion. Commercially available cell culture inserts (Transwell® permeable supports 3460) 170 
were obtained from Corning Inc. (Acton, MA, USA). Calcein, sodium fluorescein, rhodamine 171 
123, rhodamine B, rhodamine B isothiocyanate, atenolol, metoprolol tartrate, timolol maleate, 172 
nadolol, acebutolol hydrochloride and alprenolol hydrochloride (Sigma-Aldrich Co., St. 173 
Louis, MO, USA) served as model drugs. Polymyxin B (PMB), minocycline hydrochloride 174 
and ciprofloxacin hydrochloride (Sigma-Aldrich Co., St. Louis, MO, USA) were employed as 175 
anti-infective agents. All reagents for ultra-high performance liquid chromatography 176 
(UHPLC) were purchased from VWR (Radnor, PA, USA). All other chemicals and solvents 177 
were of at least analytical grade. 178 
 179 
2.2 Methods 180 
 181 
2.2.1 Langmuir trough experiments 182 
Surface pressure-area π-A measurements of lipid monolayers composed of pure bacteria-183 
relevant PLs (POPE, POPG, CL), their 70:20:10 weight mixture [21], or pure PC were 184 
performed using a thermostated Langmuir film trough (775.75 cm2, Biolin Scientific, Finland) 185 
enclosed in a plexiglas box. Experiments were performed at 294 and 303 K (21±1 °C and 186 
30±1 °C respectively). PLs were dissolved in a mixture of chloroform and methanol (9:1 v/v) 187 
to form solutions of 1 x 1015 molecules/µl. These solutions were then used to spread PLs at 188 
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the air/buffer interface, following subphase cleaning by suction. After PL deposition, the 189 
system was left for 15 min to allow complete evaporation of the organic solvents. Monolayer 190 
compression was then performed at a speed of 5 Å2 *molecule-1 *min-1. The results reported 191 
are mean values of at least two measurements. The surface compressional moduli (K) of 192 
monolayers were calculated from equation (1): 193 
 194 
 K= -A*(
dπ
dA
)                          (1) 195 
 196 
where A is the PL molecular area (Å2), dπ the surface pressure change (mN/m) and dA is the 197 
change in the molecular area. 198 
 199 
2.2.2 Model preparation 200 
Both the bacterial IM and the mammalian comparator model were produced by adapting the 201 
PVPA approach [20]. Liposomes composed of bacteria- or mammal-relevant PLs were first 202 
prepared via the lipid film hydration method [22]. Briefly, POPE, POPG and CL were used in 203 
a 70:20:10 weight ratio, as a bacteria-specific PL mixture. PC was used as mammal-specific 204 
PL. POPE, POPG and CL, or PC alone were dissolved in a mixture of chloroform and 205 
methanol (3:1, 5 ml) in a round-bottom flask (250 ml). Organic solvents were then removed 206 
under reduced pressure (1 h: 200 mbar, 30 min: 40 mbar; 70 °C (bacteria-specific PL 207 
mixture); 55 °C (mammal-specific PL)) using a Rotavapor R-205 (BÜCHI Labortechnik 208 
GmbH, Essen, Germany) in order to form a thin lipid film. Phosphate buffered saline (PBS; 209 
adjusted to pH 7.4) containing ethanol (10% v/v) was used to rehydrate the lipid film to obtain 210 
the liposome dispersions (6% w/v total lipids). Afterwards, liposomes were sonicated for 1 h 211 
and subsequently extruded (10 times; at 70 °C in case of the bacteria-relevant liposomes and 212 
55 °C in case of the mammal-relevant liposomes), using a Liposofast L-50 extruder (Avestin 213 
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Europe GmbH, Mannheim, Germany). Both IM and mammalian comparator models were 214 
then prepared by three consecutive cycles of liposome addition (75 µl each) onto filter 215 
supports, followed by centrifugation (30 min, 1040 g; Hettich Rotina 420 R, Hettich GmbH, 216 
Tuttlingen, Germany) and oven-drying (50 min, 50 °C), with a final freeze-thaw step (-80 °C, 217 
20 min; 45 °C for 20 min). 218 
 219 
2.2.3 Liposome size and surface charge measurements 220 
The hydrodynamic diameter and size distribution of liposomes was measured in PBS 221 
(adjusted to pH 7.4) using dynamic light scattering, while surface charge (ζ-potential) was 222 
determined (in the same medium) using laser doppler micro-electrophoresis (Zetasizer Nano 223 
ZS, Malvern Instruments, UK).  224 
 225 
2.2.4 Confocal Raman microscopy 226 
Confocal Raman microscopy analysis was carried out to investigate the integrity of IM and 227 
mammalian comparator model lipid coatings using a WITec alpha 300R+ imaging system 228 
(WITec GmbH, Ulm, Germany), with an Olympus 50 x objective (N.A. 0.35). The excitation 229 
source was a diode laser with a wavelength of 785 nm (50 mW). Models were analyzed 230 
following preparation, and after 5 h incubation in Krebs-Ringer buffer (KRB) at 37 °C 231 
without any further sample alteration. A confocal pinhole of 100 μm rejected signals from 232 
out-of-focus regions. Raman spectra were acquired every 100 μm along the x- and y-axis 233 
across the entire model membrane area, with an integration time of 4 s. Cosmic ray removal 234 
and background subtraction were applied to all spectra, which were then processed using 235 
hierarchical cluster analysis and basis analysis as multivariate methods for data processing, 236 
and converted into spatially-resolved false-color images using WITec Project Plus software 237 
(WITec GmbH, Ulm, Germany).  238 
 239 
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2.2.5. Laser scanning interferometry 240 
Model topography was analyzed via a LEXT OLS4000 3D Laser Measuring Microscope 241 
(Olympus AG, Tokyo, Japan), using a 405 nm semiconductor laser and a 20 x objective lens. 242 
Transwell® membranes with PL coatings were cut out of the plastic Transwell® holder 243 
surround and fixed on sample holders. Five representative membrane areas with an image size 244 
of approximately 5.6 mm2 each were analyzed. The center of the overall model surface was 245 
denoted as area 1. The center of further imaged edge areas was set at a distance of 3000 µm 246 
from the upper (2), right (3), bottom (4) and left (5) margin of the overall membrane surface.  247 
 248 
2.2.6 Scanning electron microscopy 249 
For scanning electron microscopy (SEM) investigations, freshly prepared model membranes 250 
were first freeze-dried (Christ alpha 2-4 plus, Martin Christ Gefriertrocknungsanlagen GmbH, 251 
Osterode am Harz, Germany). As for laser scanning interferometry, Transwell® membranes 252 
with PL coatings were then cut out of the plastic holder surround; filter membranes were 253 
subsequently removed. Vertical cross-sections of model membranes prepared using a scalpel 254 
were then sputtered with gold, placed in a vertical manner on sample grids and subsequently 255 
analyzed via SEM (Zeiss EVO HD 15, Carl Zeiss AG, Oberkochen, Germany). 256 
 257 
2.2.7. Permeability investigations 258 
For investigation of permeability behavior, transport studies were performed with at least 6 259 
repetitions from 2 individual experiments. IM and mammalian comparator model-permeated 260 
amounts of fluorescent dyes and ß-blockers were determined, as model compounds. Amounts 261 
of permeated ciprofloxacin and minocycline (with and without 1 h of model pre-incubation 262 
with 15.4 µM PMB), as well as an AlexaFluor® 488-labeled functionalized fatty acid moiety 263 
of the muraymycin A series of nucleoside antibiotics, together with corresponding reference 264 
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compound (both synthesized in-house according to Ries et al. [23]), were determined as anti-265 
infective substances.  266 
 267 
Prepared model membranes on Transwell® filter inserts were placed in cell culture plates and 268 
pre-incubated to rehydrate and equilibrate the system with pre-warmed KRB (pH 7.4, 37 °C) 269 
for 30 min (upon which electrical resistance (ER) values were seen to stabilize, see 270 
Supplementary Material). Following KRB removal, 520 µl of drug solution in KRB, in each 271 
case at a concentration calculated in order to ensure sink conditions and adjusted to pH 7.4 272 
(see Supplementary Material Tables S1 and S2, 1.27 µM in case of the functionalized fatty 273 
acid moiety and reference compound) was added to the apical compartment of each culture 274 
plate well (donor). A 1.5 ml volume of pre-warmed KRB was also added to the basolateral 275 
compartment (acceptor). A 20 µl volume of drug solution in KRB was immediately removed 276 
from the apical compartment, and employed to accurately measure the starting donor 277 
concentration. Samples of 200 µl were taken from the basolateral compartment of culture 278 
plate wells after 0, 0.5, 1, 1.5, 2, 2.5, 3.5 and 4.5 h, and used to quantify the permeated 279 
amount of applied compounds (see below). The removed volume was replaced with an equal 280 
volume of pre-warmed KRB in order to maintain sink conditions. Cell culture plates 281 
containing coated Transwell® filter inserts were placed on an orbital shaker (IKA®-Werke 282 
GmbH and Co KG, Staufen, Germany) set at 150 rpm and kept at 37 °C in an incubator for 283 
the duration of transport studies.  284 
  285 
2.2.8. Quantification of permeated compound/drug amount and permeability calculations 286 
A Tecan Infinite® M200 plate reader (Tecan GmbH, Crailsheim, Germany) was used to 287 
determine the permeated amount of fluorescent dyes (see Supplementary Material Table S1). 288 
A Dionex Ultimate® 3000 UHPLC with an Accucore column (RP 18, 150 mm x 2.1 mm, 2.6 289 
µm, Thermo Fisher Scientific Co., Waltham, MA, USA) was used to quantify the permeated 290 
12 
 
amount of ß-blockers, ciprofloxacin and minocycline in transport studies. ß-blocker 291 
quantification was carried out using a binary solvent system (A = 36.6 mM Na2HPO4 + 33.4 292 
mM triethylamine adjusted to pH 3; B = acetonitrile) as eluent in different ratios, depending 293 
on the analyte; the flow rate and resulting compound retention time also varied (see 294 
Supplementary Material Table S2). The column oven temperature in all cases was set to 40 295 
°C. Ciprofloxacin and minocycline quantification was also carried out using a binary solvent 296 
system (A= 0.02 M Na2HPO4 adjusted to pH 2.7; B= acetonitrile) as eluent in different ratios. 297 
The resulting retention time also varied (see Supplementary Material Table S2). The column 298 
oven temperature was set to 25 °C for ciprofloxacin and to 40 °C for minocycline. Permeated 299 
amounts of AlexaFluor® 488-labeled fatty acid moiety and corresponding reference 300 
compound were determined as described above for fluorescent dyes, with λexc. (nm) = 470 and 301 
λem. (nm) = 520. 302 
 303 
In all cases, the permeated compound amount was calculated in reference to calibration 304 
curves created from samples of standard concentration. The cumulative permeated compound 305 
amount was then plotted as a function of time. The slope of the linear region of this curve 306 
constitutes the rate of compound flux, which was used to calculate the apparent permeability 307 
coefficient (Papp) of each compound according to equation (2): 308 
Papp (cm/sec) = J/(A*c0)          (2) 309 
 310 
where J is the substance flux (mg/sec), A the surface area of the Transwell® filter insert (cm2) 311 
and c0 the initial compound concentration (mg/ml). 312 
 313 
2.2.9. Statistical analysis: 314 
Where appropriate, presented numerical data represent mean  standard error of the mean 315 
(SE). Student’s t-test was employed where relevant to evaluate significant differences (*=P < 316 
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0.05, ***=P<0.001). All tests were calculated using the software SigmaPlot version 12.5 317 
(Systat Software, Inc., San Jose, California, USA). 318 
 319 
3. Results and discussion 320 
 321 
3.1. Bacterial IM and mammalian comparator membrane model preparation, 322 
characterization and comparison 323 
 324 
3.1.1. Interfacial behavior comparison of bacteria- and mammal-relevant phospholipids 325 
Prior to IM model development and optimization the interfacial behavior of individual 326 
bacterial PLs, a bacterial PL mixture, and the mammal-specific PC was characterized using 327 
the Langmuir trough technique. Surface pressure-area measurements of pure POPE, POPG 328 
and CL monolayers were carried out, as well as the ternary mixture of POPE:POPG:CL in a 329 
relevant 70:20:10 weight ratio were carried out to confirm miscibility of the bacterial PL 330 
components. Investigation of PC lipid monolayers was also carried out in order to investigate 331 
the occurrence of any notable differences in behavior of PC and the bacterial PL mixture at 332 
the molecular level. Surface pressure-area isotherms were initially obtained at 21 °C, followed 333 
by the more physiologically relevant temperature of 30 °C (representing the highest 334 
temperature that could be applied in the experimental setup without the introduction of 335 
inaccuracies caused by buffer evaporation) (Fig. 1A). Isotherms were then used to calculate 336 
the compressibility moduli of PL monolayers (Fig. 1B).  337 
 338 
 339 
 340 
 341 
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 342 
 343 
 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
 352 
Fig. 1. Langmuir studies of bacterial IM and mammal-relevant PLs. Compression isotherms 353 
for bacteria-specific PL mixture (POPE:POPG:CL) and pure PC monolayers at 21 °C and 30 354 
°C (A), showing differences in two-dimensional organization. Corresponding compressibility 355 
moduli as a function of surface pressure for both tested monolayers are additionally depicted 356 
(B), demonstrating the greater rigidity of the POPE:POPG:CL monolayer as compared to PC.  357 
 358 
The isotherms obtained for the ternary bacterial PL mixture at 21 °C appeared to be 359 
intermediate between those of pure POPG and POPE (see Supplementary Material Fig. S1A), 360 
demonstrating that, although POPE is the major component of the ternary bacterial PL 361 
mixture, it is not the only mixture component contributing to the interfacial behavior. The 362 
influence of POPG and CL on the surface area-pressure measurements of POPE:POPG:CL 363 
monolayers, together with free energy of mixing and excess molecular area calculations (see 364 
Supplementary Material Fig. S1B, S1C) therefore implies the existence of a true lipid 365 
mixture. Comparison of the isotherms for the ternary mixture and pure PC monolayers 366 
revealed similar collapse pressures (πc) at both 21 °C and 30 °C (Fig. 1A), with values around 367 
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44 mN/m (Table 1). However, the isotherm-derived larger molecular areas for the lipid 368 
mixture at pressure onset (Aonset) and collapse (Ac) account for more expanded monolayers of 369 
the ternary mixture compared to those of pure PC. 370 
 371 
Table 1. Summary of conducted Langmuir studies. Characteristic parameters of compression 372 
isotherms, comparing the bacteria-relevant POPE:POPG:CL mixture to PC at 21 °C and 30 373 
°C. 374 
 375 
 376 
 377 
 378 
 379 
 380 
 381 
 382 
Aonset: molecular area at pressure onset, Ac: molecular area at collapse, πc: surface pressure at 383 
collapse 384 
 385 
In addition to information gained directly from the isotherms, compressibility moduli were 386 
calculated in order to determine the physical state of the PC and PL mixture monolayers at 387 
various surface pressures. Compressibility moduli below 12.5 mN/m, in the range of 13-100 388 
mN/m, from 100 to 250 mN/m and above 250 mN/m infer a gaseous, liquid expanded (LE), 389 
liquid condensed (LC) and solid state of monolayers [24], respectively. PL organization at 390 
surface pressures in the range of 25-35 mN/m is of particular interest, as this represents the 391 
pressure range considered to correspond to the internal lateral pressure found in natural 392 
membranes [25]. PC monolayers were found to be in an LE state at 21 °C within this surface 393 
Applied 
Temperature  
(°C) 
Monolayer 
Aonset 
(Å2) 
Ac 
(Å2) 
πc 
(mN/m) 
21 POPE:POPG:CL 103.0 51.6 45.4 
21 PC  97.5 43.5 42.9 
30 POPE:POPG:CL 107.5 55.8 44.9 
30 PC  92.3 45.4 43.5 
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pressure range, whereas POPE:POPG:CL monolayers appeared to be in the LC state. PC 394 
monolayers were only observed to be in the LC state at higher surface pressures, from 30-38 395 
mN/m (Fig. 1B). A similar observation was made from measurements performed at 30 °C. As 396 
a result of this interfacial analysis, the bacterial PL mixture monolayer can be regarded as 397 
being greater in molecular area and slightly more rigid compared to that of PC, at both 398 
investigated temperatures; a first indication of differences in the behavior of bacteria- and 399 
mammal-specific lipids on a molecular level can therefore be inferred.  400 
 401 
3.1.2. Bacterial IM and mammalian membrane model preparation  402 
Following initial Langmuir studies, membrane models consisting of the previously employed 403 
POPE:POPG:CL in a 70:20:10 weight ratio (bacterial IM model) and pure PC (mammalian 404 
comparator model) were prepared, via the PVPA approach [20]. In this two-step approach, 405 
liposomes consisting of the PLs of interest are first prepared, as a means to facilitate lipid 406 
deposition onto Transwell® filter supports without the use of organic solvents; liposomes are 407 
then repeatedly coated onto filter supports in order to form a lipid membrane structure. 408 
Although serving only as a means for lipid deposition, prepared POPE:POPG:CL and PC 409 
liposomes were analyzed in terms of their hydrodynamic diameter and surface charge (ζ-410 
potential) in order to confirm a consistent outcome of liposome production. Low variation in 411 
z-average and surface charge of both POPE:POPG:CL and PC liposomes confirmed the 412 
acceptability of liposome preparation (see Supplementary Material Table S3), whereas 413 
differences between bacterial and mammalian lipid liposomes (for instance with respect to 414 
size) could be regarded as an outcome of the previous elucidated differences in PL packing 415 
properties (see section 3.1.1).  416 
 417 
While PVPA models consisting of PC alone have been previously established [26-28], the 418 
primary objective of the current work was to develop a bacterial IM model. For this reason, 419 
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model preparation was adapted and optimized with respect to the use of POPE:POPG:CL. 420 
The IM-optimized preparation procedure was then applied using PC liposomes in order to 421 
produce a mammalian model which was truly comparative in nature. The procedure applied to 422 
deposit and coat liposomes on a Transwell® filter was required to result in the construction of 423 
an IM surrogate exhibiting robust permeation barrier properties, as well as a high level of 424 
stability on exposure to buffer (as would occur during transport studies). Thus, the model 425 
preparation procedure was optimized to fulfil these requirements. Deposition and coating 426 
parameters were refined by tracking the impact of parameter alterations on model barrier 427 
function in simulated transport experiments (entailing exposure to KRB, pH 7.4, 37 °C, for 5 428 
h). Barrier properties of the IM model were inferred from measurement of ER, a common 429 
means of monitoring barrier integrity in both cell-based [29,30] as well as cell-free [20] 430 
permeation models (See Supplementary Material Figure S2).  431 
 432 
The optimized preparation procedure (Fig. 2) consisted of three consecutive cycles of 433 
liposome addition to a Transwell® filter insert, centrifugation and drying, followed by a final 434 
freeze-thaw step – this step has been shown to promote liposome fusion, leading to a 435 
confluent PL coating (rather than layers of discrete liposomes) with stable barrier function 436 
[26]. The bacterial IM model constructed via this procedure showed sufficiently high and 437 
constant ER values throughout a 5 h period of exposure to KRB (see Supplementary Material 438 
Fig. S2), with no visible detachment of lipid coating from the Transwell® filter support. The 439 
described preparation procedure as optimized for IM model preparation was then used for 440 
preparation of a mammalian comparator model, by coating with PC liposomes. The 441 
comparator model also demonstrated a high and stable level of ER upon incubation with KRB 442 
(data not shown), as well as a lack of visible detachment from the Transwell® filter support.  443 
 444 
 445 
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Fig. 2. Model preparation procedure. Schematic of the two-step PVPA model preparation 446 
procedure, consisting of liposome preparation (A) and subsequent coating with liposome 447 
dispersions to form IM and mammalian comparator models (B). Liposomes consisting of 448 
POPE, POPG and CL were used to construct the bacterial IM model, while PC liposomes 449 
were employed to prepare the mammalian comparator. The final set-up of a model (blue) 450 
placed on top of a Transwell® filter support is additionally shown (C).  451 
 452 
3.1.3. Model integrity and topography assessment 453 
As described above, the optimized preparation procedure was seen in both the case of the IM 454 
and mammalian comparator model to result in a stable and robust membrane structure with 455 
appreciable barrier function. These properties can themselves be taken as an indication of a 456 
continuous and uninterrupted coating of bacteria- or mammal-specific lipids on Transwell® 457 
filter inserts. However, as any discontinuity present initially in the membrane structure or 458 
developing during transport experiments has the potential to lead to overestimation of the 459 
permeated amount of tested compounds/drugs and so distortion of resulting permeability data, 460 
it was deemed necessary to further investigate and firmly establish model integrity. 461 
Chemically selective analysis of the entire surface area of Transwell® filter inserts 462 
accommodating either the IM or mammalian comparator model was therefore performed 463 
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using confocal Raman microscopy, to determine model integrity following preparation as well 464 
as following incubation in buffer (as described above for simulated transport studies). Due to 465 
the structured surface of the models, optical topography was applied prior to confocal Raman 466 
microscopy experiments in order to adjust the focus according to the sample topography, and 467 
to characterize topography of the overall model area. Topography profiles indicated a higher 468 
surface height at the edges compared to the center in the case of both models (see Supporting 469 
Information Figure S3). This was expected due to the model preparation procedure, and is in 470 
agreement with previous investigations [31].  471 
 472 
Confocal Raman microscopy as such allows for label-free discrimination between the 473 
polyester material of the Transwell® filter inserts and the PLs of the membrane models, based 474 
on the individual spectra of the compounds. Consequently, the method allows for 475 
determination of the extent to which Transwell® filter inserts are covered with model PLs. 476 
Recorded Raman spectra were processed and subsequently converted into spatially-resolved 477 
false color images, in order to enable visualization of the integrity of lipid coating (Fig. 3, 478 
bacteria-relevant lipids of the IM model in blue, mammal-relevant lipids of the comparator 479 
model in green). Continuous bacterial PL coverage of Transwell® filter inserts was observed 480 
directly after IM model preparation, with no sign of coating defects (Fig. 3A); this continuous 481 
lipid coating was seen to remain entirely intact following 5 h incubation of the IM model in 482 
transport buffer (Fig. 3B). Likewise, the mammalian comparator model showed a continuous 483 
coverage and the absence of any defects in the PL layer immediately following preparation 484 
(Fig. 3C). Furthermore, no lipid-free Transwell® areas were observed following simulated 485 
transport experiments (Fig. 3D). Even though variations in Raman signal intensity translating 486 
to color intensity gradients could be observed in some images (especially Fig. 3D), overall 487 
intact PL coverage was confirmed by the presence of lipid-specific peaks over the entire 488 
Transwell® filter area in both models, before and after exposure to KRB. For illustration, the 489 
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individual raw Raman spectra derived from the central as well as from the outer region of 490 
coated filter membranes (marked by black and red crosses respectively) are presented below 491 
each of the Raman images in Fig. 3. The confirmed integrity of both the bacterial IM and 492 
mammalian comparator models, together with the earlier demonstrated appropriate and stable 493 
model barrier properties, therefore indicates the feasibility of compound permeability 494 
determination in the IM and comparison with the mammalian comparator. 495 
 Fig. 3. Integrity assessment of the IM and mammalian comparator model. False color images 496 
with representative single Raman spectra of central and outer regions of coated Transwell® 497 
filter inserts, showing the IM model with bacteria-relevant lipids indicated in blue before (A) 498 
and after (B) exposure to KRB, as well as mammal-relevant lipids of the comparator model in 499 
green before (C) and after (D) exposure to buffer. The presence of lipid-specific Raman peaks 500 
in all single Raman spectra at 1440 cm-1 (in raw state without any further spectral 501 
manipulation, e.g. smoothing or subtraction) confirmed the overall lipid coverage. Color 502 
intensity differences represent the variation in Raman signal intensity, not a lesser degree of 503 
lipid coverage. 504 
 505 
Having established that both the bacterial IM and mammalian comparator model were 506 
suitable for permeability investigations, the focus of further characterization shifted towards 507 
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comparison and contrast of model properties. Following initial optical topography 508 
investigations, laser scanning interferometry was employed to obtain more detailed insights 509 
into the topographical profiles of both the IM and mammalian comparator model following 510 
preparation. Hence, the bacterial IM model surface was analyzed at five representative 511 
positions (center; upper, right, bottom and left edges) each with an approximate image size of 512 
5.6 mm2, representing the maximum image size of the employed objective (Fig. 4A). A lower 513 
height maximum of approximately 73 µm, as well as a more uniform surface profile were 514 
found at the center of the IM model (Fig. 4B 1) as compared to the edge areas, which showed 515 
height maximums of up to 184 µm (Fig. 4B 2-5). The mammalian comparator model 516 
exhibited a similar contrast in surface height maximums and profile uniformity when 517 
comparing center and edge areas (Fig. 4C 1-5), indicating no marked differences in initial 518 
topography of IM and mammalian comparator models.  519 
 520 
 521 
 522 
 523 
 524 
 525 
 526 
 527 
 528 
 529 
 530 
 531 
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Fig. 4. Surface topography assessment of the IM and mammalian comparator model. 532 
Schematic of the model surface showing the location of the representative imaged areas (A). 533 
Topography of the bacterial IM model imaged at the five representative model areas (center 534 
(B1), as well as upper (B2), right (B3), bottom (B4) and left (B5) edges) is shown. The same 535 
areas of the mammalian comparator model (center (C1), upper (C2), right (C3), bottom (C4) 536 
and left (C5) edges) were additionally imaged.   537 
 538 
 539 
 540 
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3.1.4. Model thickness assessment 541 
Model thickness constitutes another parameter which potentially affects the permeability 542 
behavior of tested compounds/drugs [32]. Therefore, further to confirming model integrity 543 
and an absence of drastic differences in surface topography, it had to be ensured that the IM 544 
and the mammalian comparator model exhibited comparable values in the z dimension. 545 
Freeze-dried, vertical cross-sections of both models were therefore applied in their original 546 
orientation on sample grids and subsequently imaged and sized using SEM. Analysis of SEM 547 
images revealed similar thicknesses of the IM and the mammalian comparator model, with 548 
values of approximately 160 µm in both cases (Fig. 5). SEM images additionally indicated 549 
differences in inner model morphology, potentially occurring as a result of the differences in 550 
employed PLs; this indication was further confirmed by cryo-SEM analysis of IM and 551 
mammalian comparator models (see Supplementary Material Figure S4).    552 
 553 
 554 
 555 
 556 
 557 
 558 
Fig. 5. Thickness evaluation of the IM and mammalian comparator model. Representative 559 
SEM images of vertical cross sections of the bacterial IM (A) and mammalian comparator 560 
model (B) without underlying Transwell® filter, indicating similarity in model thickness 561 
(Images are representative of n=3 investigations, with mean values of 156  18 µm and 165  562 
6 µm for the IM and mammalian comparator model respectively). 563 
 564 
 565 
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3.2 Evaluating the impact of model lipid composition on the permeability behavior of 566 
compounds/drugs  567 
The characterization measures employed in previous sections confirmed the suitability and 568 
robustness of the bacterial IM model for transport studies, as well as the mammalian model as 569 
a relevant comparator. Bacterial IM and mammalian comparator models prepared using the 570 
same standardized procedure showed a required similarity in properties such as thickness, yet 571 
demonstrated some degree of variation on both the molecular and microscale, as a function of 572 
the different employed PLs. Whether such PL-dependent variations translated into differences 573 
in permeability behavior in the IM and the mammalian comparator model was then further 574 
investigated, to discern the importance and necessity of producing a bacterial IM model 575 
specifically employing bacterial lipids in a physiologically relevant ratio.  576 
 577 
A set of readily-quantifiable fluorescent dyes exhibiting a range of distribution coefficients at 578 
pH 7.4 (log D(pH 7.4)) was utilized in a first step in order to conduct a preliminary proof of 579 
concept study (see Supplementary Material Table S1). Point-wise differences in Papp values of 580 
such compounds in the IM and the mammalian comparator were noted, showing a trend for 581 
greater compound permeation across the IM model (Fig. 6A). This was seen to occur even in 582 
case of the negatively charged dyes calcein and fluorescein, which could potentially have 583 
been predicted to interact with negatively charged PLs (such as POPG and CL of the IM) in a 584 
repulsive way, resulting in a low level of permeation [33]. Following this encouraging 585 
preliminary result, it was decided to test a set of compounds which also varied in lipophilicity, 586 
but which showed a much greater similarity with respect to other physicochemical parameters 587 
(Table 2). For this purpose β-blockers were selected, as a standard compound set frequently 588 
employed in cell- [34] and lipid-based [35,36] in vitro models for determination of 589 
discriminatory capabilities. Utilizing this set of compounds additionally allowed for 590 
permeability comparisons of the original PC-containing PVPA model with the current 591 
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mammalian comparator, further confirming its appropriateness to serve as a reference model 592 
in the current work (see Supplementary Material Figure S5). 593 
 594 
Table 2. Important physicochemical parameters of employed ß-blockers.  595 
ß-blocker log D(pH 7.4)
a) Mw (g/mol) PSA (A
2)b) 
H-bond 
donors/acceptorsb) 
Atenolol -1.29 266.3 94.6 3 / 4 
Metoprolol -0.16 267.4 58.4 2 / 4 
Timolol 0.03 316.4 85.2 2 / 8 
Nadolol 0.68 309.4 88.8 4 / 5 
Acebutolol 0.83 336.4 92.8 3 / 5 
Alprenolol 1.38 249.3 43.7 2 / 3 
PSA: polar surface Area 596 
a) Values from Zhu et al.[37])  597 
b) Values from Pubchem 598 
 599 
Pair-wise comparisons of β-blocker permeability data again revealed significant point-wise 600 
differences in Papp values (Fig. 6B), with a higher degree of permeation noted in the case of 601 
the IM model in contrast to the mammalian comparator across the entire tested range of 602 
compound lipophilicities. This observation further confirms the impact of model lipid 603 
composition on compound permeability behavior. 604 
 605 
 606 
 607 
 608 
 609 
 610 
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 614 
 615 
 616 
 617 
 618 
 619 
 620 
 621 
 622 
 623 
 624 
 625 
 626 
 627 
Fig. 6. Permeability experiment results of model compounds. Papp values of fluorescent dyes 628 
(A) and ß-blockers (B), both in order of increasing lipophilicity, in the bacterial IM and 629 
mammalian comparator model. Values represent mean  SE; n≥9 from 3 individual 630 
experiments; *=P<0.05, ***=P<0.001. 631 
 632 
 633 
 634 
 635 
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3.3 Permeation and interaction of anti-infectives with the IM model in comparison to the 636 
mammalian comparator model 637 
The assessment and comparison of model compound permeability in the IM and mammalian 638 
comparator model demonstrated an impact of the PL composition on compound permeation. 639 
It was then further investigated whether this also applies in the case of anti-infective 640 
compounds. Ciprofloxacin and minocycline, antibiotics from two different classes which need 641 
to cross the IM to reach their target [38], were therefore tested and compared in both models. 642 
The results again revealed significant differences in Papp values, with both antibiotics 643 
permeating across the IM model to a greater extent than the mammalian comparator (Fig. 644 
7A). The employment of bacteria-specific lipids in a permeation model of the IM (as well as 645 
in further bacterial envelope model development) is therefore deemed to be of great 646 
importance, in order to avoid underestimation of compound permeability - a problem which 647 
could be even further exacerbated when additional permeation barriers of the bacterial cell 648 
envelope (such as the OM) are taken into account. 649 
 650 
In a further step, an additional antibiotic, PMB, was employed in conjunction with either 651 
ciprofloxacin or minocycline, in order to investigate the existence of functional similarity 652 
between the bacterial IM model and the Gram-negative bacterial inner membrane itself. PMB 653 
is known to interact in an electrostatic manner at in cellulo assay concentrations [39] with 654 
acidic PLs such as POPG and CL, as found in the Gram-negative bacterial inner membrane 655 
[40,41]; this interaction is followed by insertion into the membrane structure, pore formation 656 
and subsequent weakening of the membrane barrier function. In contrast, at similar PMB 657 
concentrations, no such interaction and disruption is observed with membranes containing 658 
overall electroneutral PLs like PC [40], as present in the mammalian comparator model. As a 659 
result of its permeabilizing effect on the Gram-negative inner membrane, PMB may be used 660 
clinically in a combination therapy approach together with other antibiotics such as the 661 
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currently employed minocycline [42,43], in order to provide enhanced cytoplasmic entry and 662 
target access. To determine whether this scenario was reflected in the current in vitro 663 
approach, both models were incubated with PMB in a relevant in cellulo assay concentration, 664 
as previously shown to affect the IM of Escherichia coli [40]. Ciprofloxacin or minocycline 665 
were then applied to the models, and compound permeation was again assessed. Both 666 
ciprofloxacin and minocycline showed significantly higher Papp values in the IM model 667 
following PMB treatment (Fig. 7B), whereas no significant difference in Papp was noted for 668 
either antibiotic in the mammalian comparator model as a result of incubation with PMB (Fig. 669 
7B). The observed permeabilization of the IM model (and corresponding lack of effect in the 670 
mammalian comparator model) confirms a functional similarity of this structure to the Gram-671 
negative bacterial inner membrane. This study therefore provides a clear example of the 672 
superior capacity of the bacterial IM model for evaluation of anti-infective permeation, further 673 
highlighting the importance of employing bacteria-specific lipids in model development. 674 
 675 
 676 
 677 
 678 
 679 
 680 
 681 
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 683 
 684 
 685 
  686 
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 702 
 703 
Fig. 7. Permeability experiment results of anti-infectives. Papp values of ciprofloxacin and 704 
minocycline in the bacterial IM and mammalian comparator model are shown (A), and are 705 
compared with Papp values following pre-incubation of both models with PMB (B). Values 706 
represent mean  SE; n=6 from 2 individual experiments; *=P<0.05, n.s. = not significant.  707 
  708 
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3.4 Comparison of the IM model to an established vesicle-based assay 709 
Following clear demonstration of the advantage and need for the bacterial IM model, the IM 710 
model permeation of an anti-infective-derived structure was investigated in a final, small scale 711 
exploratory study, to allow for clear comparison of data obtained with the current model to 712 
that derived from an established anti-infective permeation assay. In this respect, a 713 
hydroxyguanidine-functionalized fatty acid moiety derived from the muraymycin A-series of 714 
nucleoside antibiotics was chosen – this structure is proposed to account for the increased 715 
activity of the A-series congeners in comparison to other muraymycins, due to its ability to 716 
facilitate an increase in membrane permeability [44,45]. Recently, a simplified model system 717 
was employed to experimentally validate this proposed. In this respect, the hydroxyguanidine-718 
functionalized fatty acid moiety, covalently linked to a fluorophore (AlexaFluor 488), was 719 
applied in a vesicle-based in vitro model (not entirely utilizing bacteria-relevant PL 720 
components) [23]. For comparison, a reference compound, lacking the hydroxyguanidine-721 
functionalized fatty acid motif, was employed. The functionalized fatty acid was observed to 722 
permeate into lipid vesicles to a greater extent than the reference compound, assessed by 723 
evaluating the fluorescence intensity inside vesicles relative to background; furthermore, the 724 
functionalized fatty acid was seen to accumulate at the membrane interface right after the 725 
addition of the compound to the immobilized vesicles [23]. However, it could not be 726 
elucidated if this accumulation corresponded to a rapid permeation of the compound, due to 727 
insufficient assay sensitivity. 728 
 729 
In the current work, as for the previous vesicle-based study, the permeability of the ω-730 
hydroxyguanidinylated fatty acid conjugate was assessed in comparison to the reference 731 
compound composed of the fluorescent label and linker alone (see Supplementary Material 732 
Figure S6). Higher permeation rates as well as a significantly higher Papp value were found for 733 
the functionalized fatty acid as compared to the reference compound in the bacterial IM 734 
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model (Fig. 8), confirming the previous findings of the vesicle-based assay [23]. A further 735 
very notable result from the kinetically-resolved data as shown in Fig. 8A is the high 736 
permeated amount of the functionalized fatty acid conjugate at 0 h. This observation strongly 737 
suggests that the previously noted rapid accumulation effect does seem to correlate with 738 
immediate membrane permeation, followed by a second permeation phase. This two-phase 739 
model for the permeation of the functionalized fatty acid conjugate could only be derived 740 
from kinetically-resolved data as facilitated by use of the IM model, thus further highlighting 741 
the relevance of this new approach. 742 
 743 
 744 
 745 
 746 
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 749 
 750 
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 775 
Fig. 8. Permeability experiment results of employed functionalized fatty acid moieties. 776 
Permeation rate and extent of the hydroxyguanidinylated fatty acid and reference compound 777 
(A), showing a permeability enhancing effect of the functionalized fatty acid moiety. The 778 
finding is also reflected in the calculated Papp values (B), additionally highlighting the 779 
advantage of the IM model for quantification of permeation processes and assessment of the 780 
permeation kinetics of tested compounds. Values represent mean  SE; n=9 from 3 individual 781 
experiments; ***=P<0.001. 782 
 783 
  784 
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4. Conclusion 785 
We herein report the successful development of a stable and robust in vitro permeation model 786 
of the Gram-negative bacterial IM, composed of bacteria-relevant PLs in a physiological 787 
ratio. Characterization of the IM model and its components from the molecular level to the 788 
macroscale, and comparison with an identically-produced model created from mammal-789 
relevant PC indicated a number of PL-related model deviations. These deviations were 790 
ultimately shown to translate to significant differences in permeability of both model 791 
compounds as well as anti-infectives as a function of model PL composition. The ability of 792 
the novel IM model setup to provide quantitative data regarding the rate and extent of 793 
compound permeation was also demonstrated, facilitating a more accurate characterization of 794 
compound permeation as well as more information-rich evaluation of drug delivery 795 
approaches across the IM models. Future work focuses on the development of an OM model, 796 
in a further step towards creating a relevant permeation model of the complete Gram-negative 797 
bacterial cell envelope.  798 
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